Start of European registration of PSURs
All Periodic Safety Update Reports (PSURS) for centrally and nationally authorized medicinal products in Europe must be submitted via the PSUR Repository as of June 13, 2016.
The PSUR Repository is a single, central platform to be used by all medicines regulatory authorities and pharmaceutical companies in the European Union to exchange information about the PSUR of medicinal products. The PSUR Repository covers only medicinal products for human use.
Consequently, marketing authorization holders must use the PSUR Repository for all PSUR submissions, with the exception of PSURs for products authorised on the basis of Article 58. When a PSUR is not sent to the Repository, the marketing authorisation holder does not comply with the legal obligation to submit a PSUR.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze